The three Sopharma AD factories - the one in Kazanlak, the Tablet production and Ampoule production in Sofia - have Nivalin in common, one of the strongest Sopharma products. Nivalin is sold in more than 10 countries outside Bulgaria, making it one of the most famous Sopharma products. It increases the intensity of the reflex centers of the spinal cord, medulla oblongata and cerebral cortex, thus influences all links of the reflex arc.
Sopharma AD notifies that for February 2018 the Company recorded an increase of sales revenues of 2% compared to the same month of 2017, including 8% increase of domestic sales and same level of export sales.
For the first two months of this year, revenues from sales increased by 1% compared to the same period of 2017, including 2% increase of export sales and same level of domestic sales.
Sopharma Group reported for the first time over BGN 1 billion in sales revenue for 2017, marking an increase of 15.9%. Over the same period, the Group achieved a 25.4% increase in operating profit, a 17.5% increase in EBITDA. Net profit declined by 16.1% due to the lack of one-off transactions that resulted in extremely high financial revenues as they were in 2016.